| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD39 / ENTPD1 |
| Uniprot No | P49961 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-510aa |
| 氨基酸序列 | MEDTKESNVKTFCSKNILAILGFSSIIAVIALLAVGLTQNKALPENVKYG IVLDAGSSHTSLYIYKWPAEKENDTGVVHQVEECRVKGPGISKFVQKVNE IGIYLTDCMERAREVIPRSQHQETPVYLGATAGMRLLRMESEELADRVLD VVERSLSNYPFDFQGARIITGQEEGAYGWITINYLLGKFSQKTRWFSIVP YETNNQETFGALDLGGASTQVTFVPQNQTIESPDNALQFRLYGKDYNVYT HSFLCYGKDQALWQKLAKDIQVASNEILRDPCFHPGYKKVVNVSDLYKTP CTKRFEMTLPFQQFEIQGIGNYQQCHQSILELFNTSYCPYSQCAFNGIFL PPLQGDFGAFSAFYFVMKFLNLTSEKVSQEKVTEMMKKFCAQPWEEIKTS YAGVKEKYLSEYCFSGTYILSLLLQGYHFTADSWEHIHFIGKIQGSDAGW TLGYMLNLTNMIPAEQPLSTPLSHSTYVFLMVLFSLVLFTVAIIGLLIFH KPSYFWKDMV |
| 预测分子量 | 82 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与CD39/ENTTPD1重组蛋白相关的文献及简要摘要：
---
1. **文献名称**：*CD39 recombinant protein enhances generation of immunosuppressive adenosine in tumor microenvironments*
**作者**：Deaglio S. et al.
**摘要**：研究证明重组CD39蛋白可通过水解细胞外ATP/ADP生成腺苷，抑制T细胞活性，增强肿瘤微环境的免疫抑制能力，为肿瘤免疫治疗提供潜在策略。
2. **文献名称**：*Targeting ENTPD1 (CD39) to improve anti-PD-1 immunotherapy efficacy in solid tumors*
**作者**：Perrot I. et al.
**摘要**：通过重组CD39蛋白阻断ATP水解途径，减少腺苷积累，逆转肿瘤微环境中的T细胞耗竭，显著增强PD-1抑制剂的抗肿瘤效果。
3. **文献名称**：*Recombinant CD39 prevents platelet aggregation and thrombosis via ATP/ADP hydrolysis*
**作者**：Hohmann J.D. et al.
**摘要**：重组CD39蛋白通过快速降解血液中的ATP和ADP，抑制血小板活化和血栓形成，为心血管疾病治疗提供新方向。
---
以上研究均聚焦于重组CD39蛋白的酶活性及其在免疫调节、肿瘤治疗或心血管疾病中的潜在应用。
CD39. also known as ENTPD1 (ectonucleoside triphosphate diphosphohydrolase 1), is a cell surface enzyme belonging to the ecto-nucleoside triphosphate diphosphohydrolase family. It plays a critical role in purinergic signaling by hydrolyzing extracellular ATP and ADP into AMP, which is subsequently converted to adenosine by CD73. This enzymatic activity regulates the balance between pro-inflammatory ATP/ADP and anti-inflammatory adenosine, impacting immune responses, vascular function, and inflammation. CD39 is expressed on various immune cells, endothelial cells, and certain tumor cells, where it modulates immune tolerance and tissue homeostasis.
Recombinant CD39 proteins are engineered to study its biological functions or develop therapeutic strategies. These proteins are typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, such as glycosylation, which are essential for enzymatic activity. Purification methods like affinity chromatography yield high-purity CD39 for research or clinical applications. Functional validation includes enzymatic assays to confirm ATP/ADP hydrolysis and binding studies with antibodies or inhibitors.
CD39 has gained attention in immunology and oncology due to its role in immunosuppressive microenvironments, particularly in tumors. Overexpression of CD39 in cancer cells or regulatory immune cells (e.g., Tregs) promotes adenosine accumulation, dampening anti-tumor immunity. Recombinant CD39 proteins serve as tools to investigate immune checkpoint pathways or screen inhibitors aiming to block its activity and enhance immune responses. Conversely, CD39 agonists are explored for mitigating excessive inflammation in autoimmune diseases. Its dual role in inflammation and immune regulation makes CD39 a versatile target for therapeutic intervention.
×
